Literature DB >> 10770527

Serum and cerebrospinal fluid cystatin C levels in vascular and Alzheimer's dementia.

J Kálmán1, J Márki-Zay, A Juhász, A Sántha, L Dux, Z Janka.   

Abstract

INTRODUCTION: Cystatin C, a cysteine protease inhibitor, has been implicated in the neurodegenerative and repair processes of the nervous system, and the deposition of the same protein together with beta amyloid peptide was found as cerebral amyloid angiopathy (CAA) in different types of dementias. OBJECTIVE AND METHODS: Because of the differential diagnostic importance, serum and cerebrospinal fluid (CSF) cystatin C levels of 24 late onset Alzheimer's demented (AD) and 16 ischemic type of vascular demented (VD) probands were compared with 17 aged control (AC) persons.
RESULTS: The serum and CSF cystatin levels were found in the normal range in all groups. The ischemic VD probands had the tendency to have higher cystatin C levels than the AD. No correlation has been found with the severity and duration of dementia and with the other measured parameters.
CONCLUSION: These results indicate that lower than normal CSF cystatin C level is not a diagnostic marker in ischemic VD and CAA related to AD.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10770527     DOI: 10.1034/j.1600-0404.2000.101004279.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  7 in total

1.  Serum cystatin C and the risk of Alzheimer disease in elderly men.

Authors:  J Sundelöf; J Arnlöv; E Ingelsson; J Sundström; S Basu; B Zethelius; A Larsson; M C Irizarry; V Giedraitis; E Rönnemaa; M Degerman-Gunnarsson; B T Hyman; H Basun; L Kilander; L Lannfelt
Journal:  Neurology       Date:  2008-09-30       Impact factor: 9.910

2.  The assessment of beta amyloid, tau protein and cystatin C in the cerebrospinal fluid: laboratory markers of neurodegenerative diseases.

Authors:  Jan Mares; P Kanovsky; R Herzig; D Stejskal; J Vavrouskova; P Hlustik; H Vranova; S Burval; J Zapletalova; V Pidrman; R Obereigneru; A Suchy; J Vesely; J Podivinsky; K Urbanek
Journal:  Neurol Sci       Date:  2009-01-20       Impact factor: 3.307

3.  Multiplexed immunoassay panel identifies novel CSF biomarkers for Alzheimer's disease diagnosis and prognosis.

Authors:  Rebecca Craig-Schapiro; Max Kuhn; Chengjie Xiong; Eve H Pickering; Jingxia Liu; Thomas P Misko; Richard J Perrin; Kelly R Bales; Holly Soares; Anne M Fagan; David M Holtzman
Journal:  PLoS One       Date:  2011-04-19       Impact factor: 3.240

4.  Urinary alpha1-antichymotrypsin: a biomarker of prion infection.

Authors:  Gino Miele; Harald Seeger; Denis Marino; Ralf Eberhard; Mathias Heikenwalder; Katharina Stoeck; Max Basagni; Richard Knight; Alison Green; Francesca Chianini; Rudolf P Wüthrich; Christoph Hock; Inga Zerr; Adriano Aguzzi
Journal:  PLoS One       Date:  2008-12-05       Impact factor: 3.240

5.  Changes in Serum Cystatin C Levels and the Associations With Cognitive Function in Alzheimer's Disease Patients.

Authors:  Xueping Chen; Yan Huang; Ting Bao; Fu Jia; Ruwei Ou; Qianqian Wei; Yongping Chen; Jiao Liu; Jing Yang; Huifang Shang
Journal:  Front Aging Neurosci       Date:  2022-01-28       Impact factor: 5.750

Review 6.  Blood-Based Proteomic Biomarkers of Alzheimer's Disease Pathology.

Authors:  Alison L Baird; Sarah Westwood; Simon Lovestone
Journal:  Front Neurol       Date:  2015-11-16       Impact factor: 4.003

7.  Association Between Cystatin C and Cardiac Function and Long-Term Prognosis in Patients with Chronic Heart Failure.

Authors:  Xilin Wu; Ge Xu; Shiming Zhang
Journal:  Med Sci Monit       Date:  2020-02-16
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.